Integra Therapeutics

Integra Therapeutics: Develops next-generation gene writing tools for safer, more efficient advanced therapies. BioTech · Seed · Barcelona, Spain. Rated…

Develops next-generation gene writing tools for safer, more efficient advanced therapies.

Preliminary profile · public data only

Startup24 listed Integra Therapeutics from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

• Category: BioTech (Gene writing and advanced therapies)
• Stage: Seed
• Location: Barcelona, Spain

Startup24 rating: 69/100

Integra Therapeutics is a well-funded seed-stage biotech with a scientifically differentiated FiCAT gene-writing concept and relevant scientific, translational, and commercial leadership.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

• How the score is calculated
• Browse the catalogue

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.